Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Economists warn of three major risks: technology bubble, tariff policy, and geopolitics

Economists warn of three major risks: technology bubble, tariff policy, and geopolitics

Bitget2024/12/29 21:25

According to NBD, 2024 is about to pass. Looking back on the past year, against the backdrop of continued AI fever, the Fed's shift towards easing and the upcoming "Trump 2.0", all three major US stock indices have continuously refreshed historical records in 2024. The S&P has closed at a record high nearly 60 times within the year, NASDAQ has broken through 20,000 points for the first time in history, and Dow Jones has stood above 45,000 points for the first time. However, there are also voices of warning in the market. Bank of America believes that the biggest risk in 2025 will be a tech bubble. In an interview with reporters, Dr David Seif , chief economist for developed markets at Nomura warned that tariffs and geopolitical shocks are two biggest potential risks; among them tariffs are most likely to interrupt US bull market.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss